Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 12:30 PM
Ignite Modification Date:
2025-12-25 @ 12:09 PM
NCT ID:
NCT02408861
Group ID:
EG003
Title:
Dose De-escalation Nivolumab 240 mg and Ipilimumab 1mg/kg (Stratum 2)
Description:
Nivolumab 240 mg and Ipilimumab 1mg/kg (Dose level 2); Stratum 2: participants with lymphocyte T CD4+ count between 100-200/mm3;
Participants will be treated with 240 mg of nivolumab and 1 mg/kg of ipilimumab will be added to evaluate combination therapy (dose level 2) with one dose de- escalation allowed. No intra-participant dose escalations will be allowed. The safety evaluation period is 6 weeks at a given dose level.
Deaths Number Affected:
2
Deaths Number At Risk:
None
Serious Number Affected:
2
Serious Number At Risk:
4
Other Number Affected:
3
Other Number At Risk:
4
Study:
NCT02408861
Results Section:
NCT02408861
Adverse Events Module:
NCT02408861